2024-10-05 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report

**1. Performance and Comparison:**

Pfizer Inc. (PFE) is a multinational pharmaceutical corporation, known for its wide range of medicines and vaccines. Over the given period, PFE has underperformed the S&P 500 (VOO), with a cumulative return of -12.88% compared to VOO's 131.45%. This places PFE at the -144.33% percentile, indicating that it has significantly lagged behind the market benchmark.  

**2. Recent Price Movements:**

* **Closing Price:** 28.61
* **5-day Moving Average:** 28.87 
* **20-day Moving Average:** 29.25
* **60-day Moving Average:** 29.28

The recent price movements indicate a slight downward trend, as the closing price is below all three moving averages. However, the difference is relatively small, suggesting potential for a bounce back in the near future. 

**3. Technical Indicators:**

* **RSI:** 40.96 - This indicates that PFE is in a neutral to slightly oversold territory. 
* **PPO:** -0.34 - This indicates a bearish momentum, suggesting a potential for further price decline.
* **Delta_Previous_Relative_Divergence:** -3.85 - This reflects a recent short-term decline in relative performance.
* **Expected Return:** 0.0% - This indicates that based on historical performance relative to VOO, there is currently no expectation for a significant outperformance in the next five years.

**4. Recent Earnings and Outlook:**

| Date       | EPS  | Expected EPS |
|------------|------|--------------|
| 2024-07-30 | 0.6  | 0.458        |
| 2024-05-01 | 0.82 | 0.516        |
| 2024-01-30 | 0.1  | -0.19        |
| 2023-10-31 | -0.17| -0.32        |
| 2023-08-01 | 0.67 | 0.56         |

The most recent earnings report for the quarter ending July 30th, 2024, showed that PFE exceeded analysts' expectations, with EPS of 0.6 compared to the expected 0.458. This positive earnings surprise could indicate a positive outlook for future performance. 

**5. News and Recent Issues:**

Recent market outlooks for PFE are mixed. Some analysts cite the recent positive earnings report and continued strong performance of its vaccine and oncology products as positive factors. However, others express concerns about potential competition in the market, the impact of slowing economic growth, and the overall uncertain global environment.

* **FINBOLD**: While PFE has faced some challenges in recent quarters, its strong patent portfolio and research and development capabilities are considered strengths. 
* **Analyst Opinions**: Analyst opinions on PFE range from "Buy" to "Hold," with some expressing caution due to the current market conditions. 

**6. Comprehensive Analysis:**

Overall, PFE currently appears to be facing a period of relative underperformance. Its recent earnings report was positive, but concerns remain about its future growth potential.  While PFE's core businesses are performing well, the current market conditions present challenges, and the company's long-term performance may be affected by the overall economic outlook. 

**7. Recommendation:**

Investors seeking potential growth in the near term may want to explore other options. However, PFE's strong position in the pharmaceutical market and its commitment to research and development makes it a potentially viable long-term investment for investors seeking a diversified portfolio.  

**Disclaimer:** This analysis is for informational purposes only and should not be considered financial advice. Please consult with a financial professional before making any investment decisions. 
